Table 1 Patients and treatment characteristics.
Characteristics (N = 100) | No. patients | % |
|---|---|---|
Age | ||
< 60 years | 38 | 38.0% |
60–69 years | 34 | 34.0% |
≥ 70 years | 28 | 28.0% |
Sex | ||
Men | 77 | 77.0% |
Women | 23 | 23.0% |
KPS | ||
90–100 | 30 | 30.0% |
70–80 | 58 | 58.0% |
< 70 | 12 | 12.0% |
Extra cranial metastasis | 42 | 42% |
DS-GPA | ||
0–1 | 9 | 9.0% |
1.5–2 | 42 | 42.0% |
2.5–3 | 41 | 41.0% |
3.5–4 | 7 | 7% |
RPA | ||
1 | 28 | 28.0% |
2 | 59 | 59.0% |
3 | 12 | 12.0% |
Histology of primitive tumor | ||
Adenocarcinoma | 69 | 69.0% |
SCC | 23 | 23.0% |
Other | 8 | 8.0% |
Number of previous chemotherapy lines (N = 98) | ||
0 | 47 | 48.0% |
1 | 32 | 32.7% |
≥ 2 | 19 | 19.4% |
Primary tumor control before SRT (N = 99) | ||
No | 22 | 24.2% |
Yes | 45 | 45.5% |
Synchronous diagnosis | 30 | 0.3% |
Clinical signs | ||
Non symptomatic | 54 | 54% |
Symptomatic | 44 | 44.0% |
Deficit | 26 | 26.0% |
Seizure | 13 | 13.0% |
Corticotherapy | 41 | 45.6% |
Synchronous or metachronous BM | ||
Synchronous | 32 | 32% |
Metachronous | 68 | 68% |
No. lesions | ||
1 | 67 | 67.0% |
2 | 23 | 23.0% |
≥ 3 | 10 | 10.0% |
Longest diameter (mm) by tumor | ||
Median (range) | 14.8 | (2–46) |
Mean (standard deviation) | 16.6 | 10.4 |
Tumor localization | ||
Posterior fossa (+ /- other) | 23 | 23% |
No posterior fossa | 77 | 77% |
Time MRI-treatment (days) | ||
Mean (standard deviation) | 27.7 | 22.5 |
Time simulation-treatment (days) | ||
Mean (standard deviation) | 18.1 | 12.1 |
Treatment schedule | ||
27 (Gy)/3 fractions | 69 | 69.0% |
18–25 (Gy)/1 fraction | 18 | 18.0% |
30 (Gy)/5 fractions | 9 | 9.0% |
Other | 4 | 4.0% |
